Press Releases

Hemorai, a leading innovator in healthcare technology, is thrilled to announce that the company has been approved for a prestigious grant from the UMass Center for Advancing Point of Care in Heart, Lung, Blood, and Sleep Diseases (CAPCaT), a member of the NIH Point-of-Care Network (POCTRN). This funding will enable Hemorai to take a significant step forward in the development of its groundbreaking wearable technology designed to monitor pregnancy and post-delivery health.

The grant will be used to miniaturize Hemorai's existing technology into a wearable patch, providing a compact and effective solution for real-time monitoring. This new device will be pivotal in improving maternal health by enabling continuous monitoring of vital signs, specifically focused on detecting early warning signs of complications in pregnancy and after delivery.

Hemorai's commitment to providing innovative, non-intrusive solutions aligns perfectly with CAPCaT's mission to improve health outcomes, especially in underserved and remote communities. By leveraging this grant, Hemorai aims to enhance its technology to ensure greater accessibility and timely intervention for maternal health, ultimately contributing to the broader fight against maternal mortality and morbidity.

Hemorai's CEO, Hector Torres, expressed enthusiasm about the project: "We are incredibly excited about the potential impact of this grant on our mission to improve maternal health outcomes. This funding will enable us to transform our technology into a wearable solution that will empower healthcare providers and individuals to monitor and respond to critical health needs in real-time. We look forward to advancing this project and contributing to the health and well-being of mothers worldwide."

As part of the award, Hemorai will present its wearable solution at the 2025 Point of Care Showcase in Boston, providing an opportunity to share their progress and vision with industry leaders, potential investors, and healthcare professionals.

Hemorai, a trailblazer in healthcare technology, is proud to announce that the company has been selected as one of the winners of the prestigious MeHi Digital Health Sandbox Program. This award provides Hemorai with the opportunity to conduct clinical validation under the guidance of the esteemed UMass Chan Medical School, further advancing the company's mission to improve maternal health through innovative wearable technology.

The clinical validation study will focus on providing evidence of the efficacy and application of Hemorai's wearable technology, specifically in the context of patients with darker skin tones. This study is critical for expanding the usability of Hemorai's device and addressing disparities in current medical technologies, which often have limitations in accurately monitoring vital health indicators for people with darker skin.

"We're thrilled to partner with UMass Chan Medical School and the MeHi program to take the next step in proving the value of our technology," said Hector Torres, CEO of Hemorai. "This funding allows us to conduct clinical trials that will provide the necessary evidence to confirm that our technology is not only effective but also more inclusive and accurate for diverse patient populations. We believe this validation will help us address a major gap in healthcare and improve the outcomes for individuals who have been underserved by traditional medical devices."

The MeHi Digital Health Sandbox Program, led by the Massachusetts Technology Collaborative (MassTech), offers funding and resources to digital health startups that are working on promising technologies. Hemorai will leverage this partnership to conduct trials that will ultimately provide essential data on the efficacy of its wearable device, which continuously monitors vital signs like oxygen saturation and hemoglobin levels in a non-invasive manner.